Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Gastroenterology
Published in: BMC Gastroenterology 1/2008

Open Access 01-12-2008 | Research article

Bile composition in Alagille Syndrome and PFIC patients having Partial External Biliary Diversion

Authors: Karan M Emerick, Marc S Elias, Hector Melin-Aldana, Sandra Strautnieks, Richard J Thompson, Laura N Bull, AS Knisely, Peter F Whitington, Richard M Green

Published in: BMC Gastroenterology | Issue 1/2008

Login to get access

Abstract

Background

Partial External Biliary Diversion (PEBD) is a surgical intervention to treat children with Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille syndrome (AGS). PEBD can reduce disease progression, and examining the alterations in biliary lipid composition may be a prognostic factor for outcome.

Methods

Biliary lipid composition and the clinical course of AGS and PFIC patients were examined before and after PEBD.

Results

Pre-PEBD bile from AGS patients had greater chenodeoxycholic/cholic acid (CDCA/CA), bile salt, cholesterol and phospholipid concentrations than PFIC patients. AGS patients, and PFIC patients with familial intrahepatic cholestasis 1 (FIC1) genotype, responded better to PEBD than PFIC patients with bile salt export protein (BSEP) genotype. After successful PEBD, AGS patients have higher biliary lipid concentrations than PFIC patients and PEBD also increases biliary phospholipid concentrations in FIC1 patients.

Conclusion

Both AGS and FIC1 patients can benefit from PEBD, and preserved biliary phospholipid concentrations may be associated with better outcomes post-PEBD.
Appendix
Available only for authorised users
Literature
1.
McDaniell R, Warthen DM, Sanchez-Lara PA, Pai A, Krantz ID, Piccoli DA, Spinner NB: Notch2 mutations cause alagille syndrome, a heterogeneous disorder of the notch signaling pathway. Am J Hum Genet. 2006, 79: 169-173. 10.1086/505332.CrossRefPubMedPubMedCentral
2.
Oda T, Elkahloun AG, Pike BL, Okajima K, Krantz ID, Genin A, Piccoli DA, Meltzer PS, Spinner NB, Collins FS, Chandrasekharappa SC: Mutations in the human jagged1 gene are responsible for alagille syndrome. Nat Genet. 1997, 16: 235-242. 10.1038/ng0797-235.CrossRefPubMed
3.
Carlton VE, Pawlikowska L, Bull LN: Molecular basis of intrahepatic cholestasis. Ann Med. 2004, 36: 606-617.CrossRefPubMed
4.
Whitington PF, Freese DK, Alonso EM, Schwarzenberg SJ, Sharp HL: Clinical and biochemical findings in progressive familial intrahepatic cholestasis. J Pediatr Gastroenterol Nutr. 1994, 18: 134-141.CrossRefPubMed
5.
Bull LN, van Eijk MJ, Pawlikowska L, DeYoung JA, Juijn JA, Liao M, Klomp LW, Lomri N, Berger R, Scharschmidt BF, Knisely AS, Houwen RH, Freimer NB: A gene encoding a p-type atpase mutated in two forms of hereditary cholestasis. Nat Genet. 1998, 18: 219-224. 10.1038/ng0398-219.CrossRefPubMed
6.
Strautnieks SS, Bull LN, Knisely AS, Kocoshis SA, Dahl N, Arnell H, Sokal E, Dahan K, Childs S, Ling V, Tanner MS, Kagalwalla AF, Nemeth A, Pawlowska J, Baker A, Mieli-Vergani G, Freimer NB, Gardiner RM, Thompson RJ: A gene encoding a liver-specific abc transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet. 1998, 20: 233-238. 10.1038/3034.CrossRefPubMed
7.
Kurbegov AC, Setchell KD, Haas JE, Mierau GW, Narkewicz M, Bancroft JD, Karrer F, Sokol RJ: Biliary diversion for progressive familial intrahepatic cholestasis: Improved liver morphology and bile acid profile. Gastroenterology. 2003, 125: 1227-1234. 10.1016/S0016-5085(03)01199-5.CrossRefPubMed
8.
Whitington PF, Whitington GL: Partial external diversion of bile for the treatment of intractable pruritus associated with intrahepatic cholestasis. Gastroenterology. 1988, 95: 130-136.CrossRefPubMed
9.
Emerick KM, Whitington PF: Partial external biliary diversion for intractable pruritus and xanthomas in alagille syndrome. Hepatology. 2002, 35: 1501-1506. 10.1053/jhep.2002.33332.CrossRefPubMed
10.
Emond JC, Whitington PF: Selective surgical management of progressive familial intrahepatic cholestasis (byler's disease). J Pediatr Surg. 1995, 30: 1635-1641. 10.1016/0022-3468(95)90440-9.CrossRefPubMed
11.
Melter M, Rodeck B, Kardorff R, Hoyer PF, Petersen C, Ballauff A, Brodehl J: Progressive familial intrahepatic cholestasis: Partial biliary diversion normalizes serum lipids and improves growth in noncirrhotic patients. Am J Gastroenterol. 2000, 95: 3522-3528. 10.1111/j.1572-0241.2000.03370.x.CrossRefPubMed
12.
Wanty C, Joomye R, Van Hoorebeek N, Paul K, Otte JB, Reding R, Sokal EM: Fifteen years single center experience in the management of progressive familial intrahepatic cholestasis of infancy. Acta Gastroenterol Belg. 2004, 67: 313-319.PubMed
13.
Kalicinski PJ, Ismail H, Jankowska I, Kaminski A, Pawlowska J, Drewniak T, Markiewicz M, Szymczak M: Surgical treatment of progressive familial intrahepatic cholestasis: Comparison of partial external biliary diversion and ileal bypass. Eur J Pediatr Surg. 2003, 13: 307-311. 10.1055/s-2003-43570.CrossRefPubMed
14.
Pawlikowska L, Groen A, Eppens EF, Kunne C, Ottenhoff R, Looije N, Knisely AS, Killeen NP, Bull LN, Elferink RP, Freimer NB: A mouse genetic model for familial cholestasis caused by atp8b1 mutations reveals perturbed bile salt homeostasis but no impairment in bile secretion. Hum Mol Genet. 2004, 13: 881-892. 10.1093/hmg/ddh100.CrossRefPubMed
15.
Smit JJ, Schinkel AH, Oude Elferink RP, Groen AK, Wagenaar E, van Deemter L, Mol CA, Ottenhoff R, Lugt van der NM, van Roon MA, et al: Homozygous disruption of the murine mdr2 p-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell. 1993, 75: 451-462. 10.1016/0092-8674(93)90380-9.CrossRefPubMed
16.
Krantz ID, Piccoli DA, Spinner NB: Clinical and molecular genetics of alagille syndrome. Curr Opin Pediatr. 1999, 11: 558-564. 10.1097/00008480-199912000-00015.CrossRefPubMed
17.
Alonso EM, Snover DC, Montag A, Freese DK, Whitington PF: Histologic pathology of the liver in progressive familial intrahepatic cholestasis. J Pediatr Gastroenterol Nutr. 1994, 18: 128-133.CrossRefPubMed
18.
Klomp LW, Vargas JC, van Mil SW, Pawlikowska L, Strautnieks SS, van Eijk MJ, Juijn JA, Pabon-Pena C, Smith LB, DeYoung JA, Byrne JA, Gombert J, Brugge van der G, Berger R, Jankowska I, Pawlowska J, Villa E, Knisely AS, Thompson RJ, Freimer NB, Houwen RH, Bull LN: Characterization of mutations in atp8b1 associated with hereditary cholestasis. Hepatology. 2004, 40: 27-38. 10.1002/hep.20285.CrossRefPubMed
19.
Knisely AS, Strautnieks SS, Meier Y, Stieger B, Byrne JA, Portmann BC, Bull LN, Pawlikowska L, Bilezikci B, Ozcay F, Laszlo A, Tiszlavicz L, Moore L, Raftos J, Arnell H, Fischler B, Nemeth A, Papadogiannakis N, Cielecka-Kuszyk J, Jankowska I, Pawlowska J, Melin-Aldana H, Emerick KM, Whitington PF, Mieli-Vergani G, Thompson RJ: Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency. Hepatology. 2006, 44: 478-486. 10.1002/hep.21287.CrossRefPubMed
20.
Wang DQ, Paigen B, Carey MC: Phenotypic characterization of lith genes that determine susceptibility to cholesterol cholelithiasis in inbred mice: Physical-chemistry of gallbladder bile. J Lipid Res. 1997, 38: 1395-1411.PubMed
21.
Heuman DM: Quantitative estimation of the hydrophilic-hydrophobic balance of mixed bile salt solutions. J Lipid Res. 1989, 30: 719-730.PubMed
22.
Bartlett G: Phosphorus assay in column chromatography. J Lipid Res. 1959, 30: 719-730.
23.
Emerick KM, Whitington PF: Clinical aspects of familial cholestasis (with molecular explanations). Curr Gastroenterol Rep. 1999, 1: 223-230. 10.1007/s11894-999-0039-x.CrossRefPubMed
24.
Alagille D, Estrada A, Hadchouel M, Gautier M, Odievre M, Dommergues JP: Syndromic paucity of interlobular bile ducts (alagille syndrome or arteriohepatic dysplasia): Review of 80 cases. J Pediatr. 1987, 110: 195-200. 10.1016/S0022-3476(87)80153-1.CrossRefPubMed
25.
Libbrecht L, Spinner NB, Moore EC, Cassiman D, Van Damme-Lombaerts R, Roskams T: Peripheral bile duct paucity and cholestasis in the liver of a patient with alagille syndrome: Further evidence supporting a lack of postnatal bile duct branching and elongation. Am J Surg Pathol. 2005, 29: 820-826. 10.1097/01.pas.0000161325.36348.25.CrossRefPubMed
26.
Williams GJ, Whitington PF, Weidman SW, Black DD, Sabesin SM: Correctable plasma lipoprotein abnormalities in infants with choledochal cysts. Pediatr Res. 1985, 19: 240-247. 10.1203/00006450-198502000-00021.CrossRefPubMed
27.
Davit-Spraul A, Pourci ML, Atger V, Cambillau M, Hadchouel M, Moatti N, Legrand A: Abnormal lipoprotein pattern in patients with alagille syndrome depends on icterus severity. Gastroenterology. 1996, 111: 1023-1032. 10.1016/S0016-5085(96)70071-9.CrossRefPubMed
28.
Gottrand F, Clavey V, Fruchart JC, Farriaux JP: Lipoprotein pattern and plasma lecithin cholesterol acyl transferase activity in children with alagille syndrome. Atherosclerosis. 1995, 115: 233-241. 10.1016/0021-9150(94)05521-J.CrossRefPubMed
29.
Heubi JE, Soloway RD, Balistreri WF: Biliary lipid composition in healthy and diseased infants, children, and young adults. Gastroenterology. 1982, 82: 1295-1299.PubMed
30.
Lykavieris P, Hadchouel M, Chardot C, Bernard O: Outcome of liver disease in children with alagille syndrome: A study of 163 patients. Gut. 2001, 49: 431-435. 10.1136/gut.49.3.431.CrossRefPubMedPubMedCentral
31.
Bojanovski M, Lukermann R, Schulz-Falten J, Sturm E, Burdelski M, Bojanovski D: Parameters of lipoprotein metabolism and cholestasis in healthy and cholestatic infants and children. Prog Lipid Res. 1991, 30: 295-300. 10.1016/0163-7827(91)90027-3.CrossRefPubMed
32.
Nagasaka H, Yorifuji T, Egawa H, Yanai H, Fujisawa T, Kosugiyama K, Matsui A, Hasegawa M, Okada T, Takayanagi M, Chiba H, Kobayashi K: Evaluation of risk for atherosclerosis in alagille syndrome and progressive familial intrahepatic cholestasis: Two congenital cholestatic diseases with different lipoprotein metabolisms. J Pediatr. 2005, 146: 329-335. 10.1016/j.jpeds.2004.10.047.CrossRefPubMed
33.
Tazawa Y, Yamada M, Nakagawa M, Konno T, Tada K: Bile acid profiles in siblings with progressive intrahepatic cholestasis: Absence of biliary chenodeoxycholate. J Pediatr Gastroenterol Nutr. 1985, 4: 32-37.CrossRefPubMed
34.
Jacquemin E, Dumont M, Bernard O, Erlinger S, Hadchouel M: Evidence for defective primary bile acid secretion in children with progressive familial intrahepatic cholestasis (byler disease). Eur J Pediatr. 1994, 153: 424-428. 10.1007/BF01983406.CrossRefPubMed
35.
Bull LN, Carlton VE, Stricker NL, Baharloo S, DeYoung JA, Freimer NB, Magid MS, Kahn E, Markowitz J, DiCarlo FJ, McLoughlin L, Boyle JT, Dahms BB, Faught PR, Fitzgerald JF, Piccoli DA, Witzleben CL, O'Connell NC, Setchell KD, Agostini RM, Kocoshis SA, Reyes J, Knisely AS: Genetic and morphological findings in progressive familial intrahepatic cholestasis (byler disease [pfic-1] and byler syndrome): Evidence for heterogeneity. Hepatology. 1997, 26: 155-164. 10.1002/hep.510260121.CrossRefPubMed
36.
Redinger RN, Passi RB: Effects of plasma cholesterol lowering agents on hepatobiliary lipid metabolism and cholesterol turnover in the rhesus monkey. Can J Physiol Pharmacol. 1979, 57: 235-241.CrossRefPubMed
37.
Stapelbroek JM, van Erpecum KJ, Klomp LW, Venneman NG, Schwartz TP, van Berge Henegouwen GP, Devlin J, van Nieuwkerk CM, Knisely AS, Houwen RH: Nasobiliary drainage induces long-lasting remission in benign recurrent intrahepatic cholestasis. Hepatology. 2006, 43: 51-53. 10.1002/hep.20998.CrossRefPubMed
Metadata
Title
Bile composition in Alagille Syndrome and PFIC patients having Partial External Biliary Diversion
Authors
Karan M Emerick
Marc S Elias
Hector Melin-Aldana
Sandra Strautnieks
Richard J Thompson
Laura N Bull
AS Knisely
Peter F Whitington
Richard M Green
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2008
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/1471-230X-8-47

Other articles of this Issue 1/2008

BMC Gastroenterology 1/2008 Go to the issue

Research article

Wnt-reporter expression pattern in the mouse intestine during homeostasis

Research article

Reduced diversity and increased virulence-gene carriage in intestinal enterobacteria of coeliac children

Research article

Plasma Pentraxin3 is a Novel Marker for Nonalcoholic Steatohepatitis (NASH)

Research article

Correlation between CD4 counts of HIV patients and enteric protozoan in different seasons – An experience of a tertiary care hospital in Varanasi (India)

Study protocol

Risk factors associated with non-alcoholic fatty liver disease in subjects from primary care units. A case-control study

Research article

Commonly used bowel preparations have significant and different effects upon cell proliferation in the colon: a pilot study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits